Longer delay of RRT does no good for critically ill severe AKI patients: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-04-16 01:45 GMT   |   Update On 2021-04-16 01:46 GMT

France: Longer postponement of renal replacement therapy (RRT) did not confer any additional benefit and is indeed harmful in critically ill patients with severe acute kidney injury (AKI) and no severe complication, finds a recent study in the journal Lancet.Delaying RRT for some time in critically ill patients with severe AKI and no severe complication is safe and allows optimization of...

Login or Register to read the full article

France: Longer postponement of renal replacement therapy (RRT) did not confer any additional benefit and is indeed harmful in critically ill patients with severe acute kidney injury (AKI) and no severe complication, finds a recent study in the journal Lancet.

Delaying RRT for some time in critically ill patients with severe AKI and no severe complication is safe and allows optimization of the medical devices use. However, there remains uncertainty on the duration for which RRT can be postponed without risk. Prof Stéphane Gaudry, Département de réanimation médico-chirurgicale, APHP Hôpital Avicenne, Bobigny, France, and colleagues aimed to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy.

For this purpose, the researchers performed an unmasked, multicentre, prospective, open-label, randomised, controlled trial in 39 intensive care units in France. Critically ill patients with severe AKI (defined as Kidney Disease: Improving Global Outcomes stage 3) were monitored until they had oliguria for more than 72 h or a blood urea nitrogen concentration higher than 112 mg/dL. 

Patients were randomly assigned in the ratio 1:1 to receive either a strategy (delayed strategy) in which RRT was started just after randomization or to a more-delayed strategy. With the more-delayed strategy, RRT initiation was postponed until mandatory indication (noticeable hyperkalaemia or metabolic acidosis or pulmonary oedema) or until blood urea nitrogen concentration reached 140 mg/dL.

The primary outcome was the number of days alive and free of RRT between randomization and day 28 and was done in the intention-to-treat population.

5336 patients were assessed between May 7, 2018, and Oct 11, 2019, out of which 278 patients underwent randomization; 137 were assigned to the delayed strategy and 141 to the more-delayed strategy. 

Key findings of the study include:

  • The number of complications potentially related to acute kidney injury or to RRT were similar between groups.
  • The median number of RRT-free days was 12 days (IQR 0–25) in the delayed strategy and 10 days (IQR 0–24) in the more-delayed strategy.
  • In a multivariable analysis, the hazard ratio for death at 60 days was 1·65 with the more-delayed versus the delayed strategy.
  • The number of complications potentially related to acute kidney injury or renal replacement therapy did not differ between groups.

"In severe acute kidney injury patients with oliguria for more than 72 h or blood urea nitrogen concentration higher than 112 mg/dL and no severe complication that would mandate immediate RRT, longer postponing of RRT initiation did not confer an additional benefit and was associated with potential harm," wrote the authors. 

Reference:

The study titled, "Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial," is published in the journal Lancet.

DOI:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00350-0/fulltext



Tags:    
Article Source : Lancet

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News